Press Release Jamison Wright 9/21/26 Press Release Jamison Wright 9/21/26 PureTech Announces Successful End-of-Phase 1 Meeting with U.S. FDA and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) Read More Press Release Jamison Wright 4/22/26 Press Release Jamison Wright 4/22/26 PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Read More Press Release Jamison Wright 12/5/25 Press Release Jamison Wright 12/5/25 PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Read More
Press Release Jamison Wright 9/21/26 Press Release Jamison Wright 9/21/26 PureTech Announces Successful End-of-Phase 1 Meeting with U.S. FDA and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) Read More
Press Release Jamison Wright 4/22/26 Press Release Jamison Wright 4/22/26 PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML) Read More
Press Release Jamison Wright 12/5/25 Press Release Jamison Wright 12/5/25 PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Read More
